4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Muscular Dystrophy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 144 ongoing clinical trials involving Muscular Dystrophy
Of the 144 trials,74 trials are in Phase III
Furthermore, 22 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Muscular Dystrophy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Muscular Dystrophy, a musculoskeletal disorder. The largest number of ongoing clinical trials for Muscular Dystrophy is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Muscular Dystrophy-related drug trials.

Muscular Dystrophy related clinical trial sponsors

Fulcrum Therapeutics Inc, Lupin Ltd, and AMO Pharma Ltd are some of the notable clinical trial sponsors involved in Muscular Dystrophy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Muscular Dystrophy

Nandrolone decanoate (Retabolil), Gabapentin (Neuropill), and Calcitonin (Seacalcit) are among the key marketed drugs involving Muscular Dystrophy.

Nandrolone decanoate (Retabolil) is a steroid with androgenic and anabolic properties. It functions via Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Agonist mechanism of action. Nandrolone decanoate is formulated in the form of injection for solution intramuscular route of administration. Nandrolone decanoate is marketed for the treatment of Muscular Dystrophy and several other indications including Breast Cancer, Glomerulonephritis, Osteoporosis, Cachexia, Diabetic Retinopathy, Anemia in Chronic Kidney Disease (Renal Anemia). Nandrolone decanoate was first approved in 2008 and is marketed in Russia by Gedeon Richter - RUS.

Gabapentin (Neuropill) is an anti-convulsant. It functions via Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Blocker; Voltage Dependent Calcium Channel Subunit Alpha2/Delta2 (CACNA2D2) Blocker mechanism of action. It is formulated as tablets for oral route of administration. Gabapentin is marketed for the treatment of Muscular Dystrophy and several other indications including Traumatic Pain, Algodystrophy (Reflex Sympathetic Dystrophy Syndrome), Postherpetic Neuralgia, Diabetic Peripheral Neuropathy, Peripheral Neuropathy (Sensory Neuropathy). Gabapentin is marketed in India by Exeltis - Ordain Health Care Global Pvt Ltd.